Valbiotis SA (DE:8JD)
FRANKFURT:8JD
8JD Stock Chart & Stats
€0.67
-€0.01(-0.67%)
At close: 4:00 PM EST
€0.67
-€0.01(-0.67%)
Day’s Range― - ―
52-Week Range€0.52 - €1.26
Previous CloseN/A
Volume0.00
Average Volume (3M)407.00
Market Cap
€31.63M
Enterprise Value€23.71M
Total Cash (Recent Filing)€8.68M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,547,350
10 Day Avg. Volume1,223
30 Day Avg. Volume407
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€3.63M
Bulls Say, Bears Say
Bulls Say
Market Focus & Scientific PositioningValbiotis targets durable consumer-health markets (dyslipidemia, prediabetes, hypertension) with science-backed, plant-based nutraceutical formulations. This strategic focus aligns with long-term demographic and chronic-disease trends and supports repeatable retail and partner revenue streams.
Manageable LeverageBalance-sheet leverage sits at moderate mid-range levels, indicating the company is not over-levered. That structural position preserves financing optionality and reduces immediate solvency pressure, allowing continued commercialization efforts or negotiated partnerships without extreme debt servicing strain.
Demonstrated Revenue ReboundA material revenue rebound in 2025 demonstrates the firm's ability to generate commercial sales after prior volatility. Durable commercialization traction, if sustained, supports margin improvement opportunities, scale benefits, and stronger partner/licensing negotiations over the medium term.
Bears Say
Sustained UnprofitabilityPersistent large operating and net losses with negative gross profit indicate the business is not yet economically viable at current scale. This structural lack of profitability limits reinvestment, stresses margins, and requires either significant scale, cost restructuring, or margin expansion to reach self-sustaining operations.
Chronic Cash BurnMulti-year negative operating and free cash flow show structural cash consumption. Ongoing cash burn forces dependence on external capital, increasing dilution and constraining strategic flexibility for R&D, marketing, or distribution investments essential to durable commercial growth.
Eroding Equity & ReturnsDeclining equity and asset bases alongside materially negative ROE indicate shareholder value dilution over time. This structural deterioration reduces balance-sheet flexibility, making future funding rounds more dilutive and weakening the firm's ability to weather setbacks or pursue opportunistic partnerships.
Valbiotis SA News
8JD FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.52 and its highest was €1.26 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €31.63M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Sep 24, 2026 which is in 105 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.204.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 35,547,350 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.314%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in DE:8JD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valbiotis SA
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.